Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 8
2005 10
2006 10
2007 6
2008 7
2009 10
2010 10
2011 5
2012 11
2013 7
2014 13
2015 14
2016 16
2017 18
2018 10
2019 23
2020 19
2021 32
2022 26
2023 24
2024 29
2025 34
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H. Ji L, et al. Among authors: zheng q. Lancet Diabetes Endocrinol. 2025 Sep;13(9):777-789. doi: 10.1016/S2213-8587(25)00141-X. Epub 2025 Jun 21. Lancet Diabetes Endocrinol. 2025. PMID: 40555243 Clinical Trial.
Reply.
Tong M, Chen F, Zheng Q, Zhu Y. Tong M, et al. Among authors: zheng q. J Infect Dis. 2021 Apr 23;223(8):1499-1500. doi: 10.1093/infdis/jiab041. J Infect Dis. 2021. PMID: 33515453 No abstract available.
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
Zhu D, Wang W, Tong G, Ma G, Ma J, Han J, Zhang X, Liu Y, Gan S, Qin H, Zheng Q, Ning J, Zhu Z, Guo M, Bu Y, Li Y, Jones CL, Fenaux M, Junaidi MK, Xu S, Pan H. Zhu D, et al. Among authors: zheng q. Nat Commun. 2024 Sep 27;15(1):8408. doi: 10.1038/s41467-024-52353-y. Nat Commun. 2024. PMID: 39333121 Free PMC article. Clinical Trial.
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, Wang H, Wu J, Shi X, Zhao S, Duan B, Zhu Y, Zhou Y, Li F, Wang X, Ling H, Wang S, Li Q, Jiang F, Yang M, Bing S, Zheng Q, Ning J, Guo M, Bu Y, Guan L, Li Y, Yang L, Guo W, Pan H, Li X. He Y, et al. Among authors: zheng q. Lancet Diabetes Endocrinol. 2025 Oct;13(10):863-873. doi: 10.1016/S2213-8587(25)00196-2. Epub 2025 Aug 22. Lancet Diabetes Endocrinol. 2025. PMID: 40854315 Clinical Trial.
331 results